Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Chapple

Showing results (81-90 of 166) with videos related to

Pageof 17
Sort By:
European Urology|December 17, 2008
Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockersChristopher Chapple, Sender Herschorn, Paul Abrams, et al.
Scientific Reports|January 11, 2018
TRPV1 enhances the afferent response to P2X receptor activation in the mouse urinary bladderLuke Grundy, Donna M Daly, Christopher Chapple, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|March 13, 2016
Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study)Francesco Montorsi, Giorgio Gandaglia, Christopher Chapple, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|July 13, 2006
Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndromePaul Abrams, Linda Cardozo, Christopher Chapple, et al.
Acta Biomaterialia|October 20, 2015
Production of ascorbic acid releasing biomaterials for pelvic floor repairNaşide Mangır, Anthony J Bullock, Sabiniano Roman, et al.
Lancet (London, England)|November 15, 2025
Urodynamic testing in refractory overactive bladder symptoms: the FUTURE study - Authors' replyMohamed Abdel-Fattah, Karen Ward, Simon Dixon, et al.
Neurourology and Urodynamics|February 8, 2013
OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivityEric Rovner, Roger Dmochowski, Christopher Chapple, et al.
The Journal of Urology|January 22, 2014
Effects of tadalafil once daily on maximum urinary flow rate in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasiaClaus G Roehrborn, Christopher Chapple, Matthias Oelke, et al.
Journal of Visualized Experiments : Jove|July 7, 2025
A Novel Surgical Technique in a Sheep Model for Suburethral Graft ImplantationRaouf Seyam, Christopher Chapple, Omar Alsulaiman, et al.
European Urology Open Science|November 29, 2023
The Effects of Age, Gender, and Postvoid Residual Volume on Catheterization Rates After Treatment with OnabotulinumtoxinA for Overactive BladderRoger Dmochowski, Christopher Chapple, Jennifer Gruenenfelder, et al.
Pageof 17

Showing results (81-90 of 166) with videos related to

Sort By:
Pageof 17
European Urology|December 17, 2008
Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockersChristopher Chapple, Sender Herschorn, Paul Abrams, et al.
Scientific Reports|January 11, 2018
TRPV1 enhances the afferent response to P2X receptor activation in the mouse urinary bladderLuke Grundy, Donna M Daly, Christopher Chapple, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|March 13, 2016
Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study)Francesco Montorsi, Giorgio Gandaglia, Christopher Chapple, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|July 13, 2006
Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndromePaul Abrams, Linda Cardozo, Christopher Chapple, et al.
Acta Biomaterialia|October 20, 2015
Production of ascorbic acid releasing biomaterials for pelvic floor repairNaşide Mangır, Anthony J Bullock, Sabiniano Roman, et al.
Lancet (London, England)|November 15, 2025
Urodynamic testing in refractory overactive bladder symptoms: the FUTURE study - Authors' replyMohamed Abdel-Fattah, Karen Ward, Simon Dixon, et al.
Neurourology and Urodynamics|February 8, 2013
OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivityEric Rovner, Roger Dmochowski, Christopher Chapple, et al.
The Journal of Urology|January 22, 2014
Effects of tadalafil once daily on maximum urinary flow rate in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasiaClaus G Roehrborn, Christopher Chapple, Matthias Oelke, et al.
Journal of Visualized Experiments : Jove|July 7, 2025
A Novel Surgical Technique in a Sheep Model for Suburethral Graft ImplantationRaouf Seyam, Christopher Chapple, Omar Alsulaiman, et al.
European Urology Open Science|November 29, 2023
The Effects of Age, Gender, and Postvoid Residual Volume on Catheterization Rates After Treatment with OnabotulinumtoxinA for Overactive BladderRoger Dmochowski, Christopher Chapple, Jennifer Gruenenfelder, et al.
Pageof 17